Radient Technologies Inc. Files Provisional Patent Application for Reducing Nicotine Levels in Tobacco

Edmonton, Alberta, CANADA

EDMONTON, Alberta, June 05, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office (the “USPTO”) for innovation related to methods for obtaining nicotine depleted tobacco, without materially altering certain desirable properties of the tobacco.

The patent application provides a method to selectively extract nicotine from tobacco via Radient’s continuous-flow microwave-assisted processing (MAP™) extraction technology and provides a composition of tobacco that is depleted in nicotine, but retains its appearance and organoleptic properties.

The invention discloses the ability of Radient’s proprietary MAP™ technology to achieve nicotine depletions of over 95% across multiple cured tobacco types, leaving the reduced nicotine tobacco intact and fit for processing into cigarettes and other combustible tobacco products.

This provisional application was first filed in the USPTO to create a priority date and allow for future filings in other selected jurisdictions, as appropriate.

The U.S. Food and Drug Administration (the “FDA”) issued an Advanced Notice of Proposed Rulemaking (ANPRM) on March 16, 2018 to explore a product standard to set the maximum nicotine level for cigarettes, so that cigarette products are minimally addictive or non-addictive. Radient is supportive of the FDA’s proposal and believes that the subject of the invention for which it has filed this provisional patent could provide a feasible solution to the reduction of nicotine from tobacco at industrially relevant volumes, while avoiding the need to implement complicated and time-consuming changes to the tobacco agricultural supply chain.

The patent application also includes methods of recovering and purifying the nicotine as a co-product. Nicotine has commercial value for inclusion in smoking cessation products and in e-liquids for use in e-cigarettes and vaping products.

Dr. Steven Splinter, Founder and CTO of Radient, stated: “Radient is committed to innovation in new and developing industries, and we see the potential market opportunity in providing a safe, effective industrial-scale method of nicotine extraction from tobacco, specifically during the primary manufacturing phase of cigarettes or other combustible tobacco products. Furthermore, a high-purity nicotine co-product could have wide-scale applications in the growing smoking cessation product market.”  

About Radient
Radient extracts natural compounds from a range of biological materials using microwave assisted processing (“MAP™”), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health and personal care markets. Since 2016, Radient has expanded its offerings to enter the cannabinoids market utilizing its MAP™ platform to process and extract cannabinoids including cannabidiol and tetrahydrocannabinol from cannabis biomass. Visit www.radientinc.com for more information.  

SOURCE: Radient Technologies Inc.

Denis Taschuk, Chief Executive Officer, dtaschuk@radientinc.com,
(780) 465-1318;  

Mike Cabigon, Chief Operating Officer, mcabigon@radientinc.com,
(780) 465-1318 

Forward Looking Information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the Company’s patent application to the USPTO; the Company’s ability to extract nicotine from tobacco; the impact of ANPRM on the tobacco industry and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.